Iqvia Holdings Inc.

IQVIA reports a 19% increase in R&D new bookings in Q2 to a record $3.15 billion. Analysts say the company’s strategic importance is strengthened in the AI era, as IQVIA sits at the center of drug development with health data and clinical services. Its Predictive Clinical Development solution is expected to significantly speed study starts and data analyses and save up to two years of development time. RBC Capital raised its price target on September 29 from $247 to $319 and rates the stock as outperform. » Mere på finanzen.net

If you had invested $1,000 in IQVIA on Sept. 15/16, 2016 (price then $77.31), the 12.935 shares would have been worth $3,485.19 at a price of $269.44 on Sept. 17, 2026, representing a gain of 248.52%. IQVIA most recently reached a market capitalization of around $44.16 billion. Stock splits and dividend payments are not included in the return calculation. » Mere på finanzen.net

Broyhill Asset Management reported that IQVIA Holdings gained 14% in Q2 after results beat expectations and request-for-proposal flow and award timing improved. The firm trimmed its IQVIA position in June and redeployed proceeds into Thermo Fisher as a portfolio-management move rather than a change in conviction. IQVIA shares closed at $265.67 on Sept. 14, up 10.68% over the past month and 42.21% over the past year, supported by rebounding pharma R&D and CRO market expansion. » Mere på finance.yahoo.com

A $100 investment in IQVIA five years ago would equal 0.384 shares today and, based on the closing price on September 10, 2026, would be worth about $98.77, a decline of 1.23%. IQVIA most recently has a market capitalization of $42.31 billion. The calculation does not account for stock splits or dividends. » Mere på finanzen.net

IQVIA, through its subsidiary, plans to issue senior notes totaling $2 billion due March 15, 2034, with a coupon of 6.375% p.a. Proceeds are intended to fully repay the existing senior notes (5.000%) due 2026, partially pay down the revolving credit facility, and cover issuance costs. The transaction is expected to close on September 23, 2026, subject to customary conditions. The notes will be offered to qualified institutional buyers in the U.S. under Rule 144A and to investors outside the U.S. under Regulation S, and the announcement drove an approximately 4.3% rise in IQVIA shares in after-hours trading. » Mere på de.investing.com